Radiology, Vol 175, 163-171, Copyright © 1990 by Radiological Society of North America
In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results
H Abdel-Nabi, RJ Doerr, HW Chan, D Balu, RF Schmelter and RT Maguire
Department of Nuclear Medicine, Veterans Administration Medical Center, School of Medicine and Biomedical Sciences, SUNY, Buffalo 14214.
A phase I/II prospective clinical trial was performed with indium-111-
labeled monoclonal antibody (MoAb) conjugate B72.3-glycyl-tyrosyl N-
epsilon-diethylenetriaminepentaacetic acid (CYT-103) in 28 preoperative
patients with biopsy-proved or suspected colorectal carcinomas.
Immunoscintigraphy was performed 2-7 days after infusion of 4.1 mCi (152
MBq) of In-111 labeled to CYT-103 at doses of 0.5, 1.0, 2.0, and 20.0 mg.
Surgical and histologic confirmation was available in all cases. Use of
In-111 CYT-103 made possible detection of 75% of colorectal carcinomas at
doses of 1.0 mg and higher, compared with only 20% detection at the 0.5-mg
MoAb dose. Immunohistochemical staining for tumor-associated glycoprotein
(TAG)-72 in resected carcinoma tissues demonstrated a positive correlation
between MoAb imaging and the percentage of cells that expressed TAG-72. One
patient suffered an adverse reaction after MoAb infusion. Human antimouse
response to CYT- 103 developed in 16% of patients.
